%0 Journal Article
%T Pattern of Failure and Treatment Results in Triple Negative Breast Cancer Patients
%A Sherif Zawawy
%A Gehan Khedr
%J Advances in Breast Cancer Research
%P 75-88
%@ 2168-1597
%D 2022
%I Scientific Research Publishing
%R 10.4236/abcr.2022.112006
%X Background: Triple negative breast cancer (TNBC) tends to present aggressively with
rapid progression and poor survival. Methods: We retrospectively
reviewed patients¡¯ files to define TNBC patients¡¯ characteristics, predictive
and prognostic factors, pattern of recurrence and survival. Results: 965
cases were identified. 147 patients (15.2%) were TNBC. 71.1% patients were
premenopausal. T2, T3, T4 tumors represented 46.1%, 32% and 14.1%,
respectively. N0, N1, N2, N3 disease represented 18.5%, 50.9%, 27.8% and 2.8%,
respectively. Stages II, III & IV
constituted 34.1%, 44.2% and 15.5%, respectively. 31.5% patients received
neoadjuvant chemotherapy with 17.7% complete pathological response. 19.5%,
35.9%, 44.6% patients had unknown, ¡Ü20 and >20 Ki67, respectively. Among non-metastatic patients (n = 108), 21.3% patients developed relapse with
median time to relapse of 11 months. 78.3% of them had visceral (88.3% lung)
metastasis, 13% bone metastasis, 21.7% brain metastasis and 13% LRR. There is significantly high risk of relapse in patients with large tumor size [T4:
66.75%, T3: 22.9%, T2: